Lido Advisors’s BioNTech BNTX Stock Holding History

Lido Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-22,257	Closed	-$2.43M	–	911
2021 Q1	$2.43M	Buy	+22,257	New	+$2.36M	0.04%	203

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Lido Advisors's BNTX Position: Q2 2021 in Review

Lido Advisors sold out of BioNTech (BNTX) in Q2 2021, closing a stake of 22,257 shares — an estimated $2.43M sold.

Lido Advisors first reported a position in BNTX in Q1 2021 and held it in 1 quarter. The position peaked at $2.43M in Q1 2021. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2021.

Lido Advisors reported no remaining BioNTech position as of Q2 2021 after selling out during the quarter.
Lido Advisors sold 22,257 BioNTech shares in Q2 2021, an estimated $2.43M.
Lido Advisors first reported a position in BioNTech in Q1 2021 and held it in 1 quarter.
Lido Advisors's BioNTech position peaked at $2.43M in Q1 2021.
283 funds tracked by Wall St. Rank held BioNTech as of Q2 2021.

Based on Lido Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.